GC녹십자홀딩스

GC Holdings shows thin profitability and a heavy drop in its share price over the past year, with a trailing net loss.

GC Holdings, a Korean healthcare and biotech holding company, reported trailing twelve-month revenue of about ₩2.49T to H1 2026 but a net loss of about ₩122B, with an operating margin of 1.2%. The shares closed at ₩9,330 on 2026-10-23, down about 41% over one year and roughly 46% below the 52-week high of ₩18,010. The balance sheet carries borrowings of about ₩1.57T against cash of about ₩85B.

What stands out

• Revenue has grown in 2025 (up 11.2%) after a weaker 2023, but net income swung to a loss of about ₩70B in 2025 after a ₩24B profit in 2024.
• Operating margin is only 1.2% on a trailing basis, and the company reports a net margin of -4.9%, so little of the operating profit reaches shareholders.
• Liabilities are about 140% of equity and borrowings are large relative to cash, which matters given the losses.
• Price-to-book is about 0.5 and the dividend yield is 3.2%, but the data gives no fair value estimate and no forward earnings, so the valuation picture is incomplete.
• Filings in 2026 include several shareholding reports and a sale of shares in another company, and no news headlines were available in the data.

What to watch

• The next quarterly or annual results, to see whether the trailing losses narrow or continue.
• Further changes in the largest shareholder's holdings and 5%+ holding reports, which appeared in the recent filings.
• Progress on debt levels relative to cash, since borrowings are far above cash in the data provided.